

The Biden effect on India Pharma Inc

Stakeholders share their views and insights on the impact of a change of guard at the White House and outline India Pharma Inc's expectations from the Biden administration

By EP News Bureau — On Dec 1, 2020

REGULATIONS/POLICIES

EXPERT OPINIONS

LATEST UPDATES



US President-elect Joe Biden (AP photo/Andrew Karnik)

Share



15,238

0

Read Article

We expect there to be an even stronger focus on generics and biosimilars

In line with the President elect's campaign promise of lowering healthcare costs, we expect there to be an even stronger focus on generics and biosimilars to introduce material savings. Localising manufacturing in the US has also been a subject of focus, though with it would come an increase in cost compared with India-based production. However, we remain open to the discussion of localising manufacturing, should the new government offer relief on pricing or provide an indicative commitment on volumes. We would be well-positioned to meet this need from both a product portfolio and capability perspective.

– Vinita Gupta, CEO, Lupin